Home Page
About us
- Overview
- Organization
Technology
- Abiprot^TM-antibody platform
- Abiprot Select^TM
Portfolio
Corporate Gouvernance
- General annual meetings
- Board of Directors and Management
Investors Relations
- Reports
News
- Press Releases
- Publications, conferences & press
Contact

Oblique Therapeutics > Corporate Gouvernance

Home Page
About us
- Overview
- Organization
Technology
- Abiprot^TM-antibody platform
- Abiprot Select^TM
Portfolio
Corporate Gouvernance
- General annual meetings
- Board of Directors and Management
Investors Relations
- Reports
News
- Press Releases
- Publications, conferences & press
Contact

Corporate Gouvernance

Contact

Oblique Therapeutics AB
info@obliquet.com

Gothenburg
Arvid Wallgrens Backe 20
413 46 Göteborg
Sweden

Stockholm
Döbelnsgatan 64
113 52 Stockholm
Sweden

About

Oblique Therapeutics is a privately held Swedish biotech developing innovative new medicines for severe diseases with a large unmet medical need focusing on pain, and advanced cancer. The company uses AbiprotTM, an in-house-invented, next-generation antibody platform that can generate antibodies with programmed function against the full human proteome.

We use cookies to improve the user experience on Oblique Therapeutics. Read more about Cookies

Approve